A large analysis of the impact of genomic and clinical features on the outcomes of 424 patients with KRAS‐mutated NSCLC identified comutations in the tumor suppressors SMARCA4, KEAP1, and CDKN2A as the most important independent determinants of inferior clinical outcomes with KRAS G12C inhibitor monotherapy (sotorasib or adagrasib) [28]. The gene discussed is KRAS; the disease is neoplasm.